Stability and compatibility of tegaserod from crushed tablets mixed in beverages and foods

American Journal of Health-System Pharmacy

Volumn 61, Issue 11, 2004, Pages 1135-1142

  Carrier, Marie Noëlle ^a   Garinot, Olivier ^b,d   Vitzling, Christian ^c  

^a NOVARTIS PHARMA K K   (Japan)

^b Novartis Pharma SAS   (France)

^c Novartis Pharma SA   (France)

^d Novartis Pharma SAS   (France)

Author keywords

Beverages; Dissolution; Food; Gastrointestinal drugs; Homogeneity; Incompatibilities; Juices; Milk; Stability; Storage; Suspensions; Tegaserod maleate; Temperature

Indexed keywords

TAP WATER; TEGASEROD; YOGHURT; GASTROINTESTINAL AGENT; INDOLE DERIVATIVE;

APPLE JUICE; ARTICLE; BEVERAGE; CACAO; COMPARATIVE STUDY; DRUG INCOMPATIBILITY; DRUG SOLUBILITY; DRUG STABILITY; FOOD DRUG INTERACTION; HAZELNUT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MILK; ORANGE JUICE; PRIORITY JOURNAL; SUSPENSION; TABLET; CHEMISTRY; DRUG STORAGE; FOOD; FREEZING; SOLUBILITY;

BEVERAGES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INCOMPATIBILITY; DRUG STORAGE; FOOD; GASTROINTESTINAL AGENTS; INDOLES; REFRIGERATION; SOLUBILITY; SUSPENSIONS; TABLETS;

EID: 5444258126     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.11.1135     Document Type: Article

References (17)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002; 97(suppl): S1-5.
2. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997; 112: 2120-37.
3. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001; 13:1327-32.
4. Gralnek IM, Hays RD, Kilbourne A et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000; 119:654-60.
5. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000; 95:67-71.
6. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002; 97 (suppl):S7-26.
7. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002; 16:1877-88.
8. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001; 15:1655-66.
9. Zelnorm (tegaserod maleate) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2002.
10. 4 receptor partial agonist with promotile activity. Clin Pharmacokinet. 2002; 41:1021-42.
11. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15:110-5.
12. Sparreboom A, de Jonge MJ, Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002; 38:18-22.
13. Wright D. Medication administration in nursing homes. Nurs Stand. 2002; 16:33-8.
14. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998; 50:375-82.
15. Spieker MR. Evaluating dysphagia. Am Fam Physician. 2000; 61:3639-48.
16. Mujica VR, Conklin J. When it's hard to swallow. What to look for in patients with dysphagia. Postgrad Med. 1999; 105:131-2,145.
17. Overgaard AB, Hojsted J, Hansen R et al. Patients' evaluation of shape, size and colour of solid dosage forms. Pharm World Sci. 2001; 23:185-8.